Skip to main content
Clinical Trials/NCT04748237
NCT04748237
Recruiting
Not Applicable

Randomized Evaluation of Coronary Computed Tomographic Angiography in Intermediate-risk Patients Presenting to the Emergency Department With Chest Pain

Karolinska Institutet1 site in 1 country1,600 target enrollmentJanuary 21, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chest Pain
Sponsor
Karolinska Institutet
Enrollment
1600
Locations
1
Primary Endpoint
The composite of death, readmission because of MI or unstable angina requiring revascularization
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The aim is to determine whether a diagnostic strategy including early coronary computed tomographic angiography in intermediate-risk patients presenting to the Emergency Department with chest pain reduces the composite endpoint of death, readmission because of myocardial infarction or unstable angina requiring revascularization.

Detailed Description

Patients presenting to the ED with chest pain or other symptoms suggestive of ACS, without acute MI but with an intermediate risk (HEART-score \>3) will after written informed consent be randomized to either a strategy with an initial CCTA or not. Patients randomized to strategy including early CCTA will receive standard care according to responsible physician and perform a CCTA as soon as possible (in most cases within 24 hours, but at least within 21 days).The result will be presented to the responsible physician who will plan further care of the patients. Patients randomized to a strategy not including early CCTA will receive further care (including examinations) according to responsible physician but not include early CCTA. These patients will often undergo a non-invasive functional test, such as Exercise-ECG, stress echocardiography or nuclear imaging according to local routines, but not always. All patients should receive optimal prevention according to current guidelines. The responsible physician will be encouraged to initiate secondary prevention measures if examinations show signs of CAD. The primary endpoint is composite of death, readmission because of MI or unstable angina requiring revascularization.

Registry
clinicaltrials.gov
Start Date
January 21, 2021
End Date
December 2025
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dr. Tomas Jernberg

Principal Investigator, Clinical Professor

Karolinska Institutet

Eligibility Criteria

Inclusion Criteria

  • Age≥18 years.
  • Within 24 hours from presenting to the ED with chest pain or other symptoms suggestive of coronary artery disease (CAD)
  • HEART-score \>3 (according to http://www.heartscore.nl/)
  • Written informed consent obtained

Exclusion Criteria

  • Any condition that may influence the patient's ability to comply with study protocol.
  • Known obstructive CAD (\>50%) or previous PCI or CABG.
  • Clear alternative diagnosis
  • Estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73m2
  • Major allergy to iodinated contrast media
  • Circumstances making high quality images unlikely.
  • Not a Swedish resident with a personal ID-number.
  • Pregnancy or breast feeding
  • Further investigation for CAD not indicated, due to limited life expectancy, quality of life or functional status
  • Previous inclusion in the trial

Outcomes

Primary Outcomes

The composite of death, readmission because of MI or unstable angina requiring revascularization

Time Frame: through study completion, an average of 5 year

death of any cause, readmission because of MI (I21) or revascularization because of unstable angina not related to the index event

Secondary Outcomes

  • Death or readmission because MI(through study completion, an average of 5 year)
  • Death(through study completion, an average of 5 year)
  • Resource use / Health care costs(through study completion, an average of 5 year)
  • Non-obstructive CAD at first invasive coronary angiography(through study completion, an average of 5 year)
  • Angina(1 year)
  • Cardiovascular death(through study completion, an average of 5 year)
  • Death, readmission because MI or stroke(through study completion, an average of 5 year)
  • Invasive coronary angiography(through study completion, an average of 5 year)
  • Use of prevention medications(1, 2 and 3 years)
  • Stroke (fatal or non-fatal)(through study completion, an average of 5 year)
  • Health-related quality of life(1 year)
  • MI (fatal or non-fatal)(through study completion, an average of 5 year)
  • Readmission because of unstable angina requiring revascularization(through study completion, an average of 5 year)
  • Re-presentation to the ED because of chest pain(through study completion, an average of 5 year)

Study Sites (1)

Loading locations...

Similar Trials